{"id":{"repo_id":"ajou","oai_identifier":"oai:repository.ajou.ac.kr:201003/1627"},"canonical_url":"https://search.dev.ndltd.org/etd/ajou/oai:repository.ajou.ac.kr:201003/1627","repository":{"repo_id":"ajou","name":"Ajou University","base_url":"http://repository.ajou.ac.kr/oai/request"},"display":{"title":"The Prevalence and Clinical Significance of Newly Sensitization to Inhalant Allergens in Toluene Diisocyanate-induced Asthmatic Patients","abstract":"BACKGROUND: It has been reported that half of toluene diisocyanate (TDI)-induced asthma patients had persistent asthmatic symptoms even after complete avoidance. We hypothesized that new sensitization to common inhalant allergens may contribute to persistent and aggravation of asthmatic symptoms. OBJECTIVE: The aim of this study is to investigate the prevalence and clinical significance of new sensitization to common inhalant allergens in patients with TDI-induced asthma. SUBJECTS AND METHODS: Thirty-six TDI induced asthma patients who had been followed for more than three years were enrolled. They were classified into two groups, newly-sensitized group and not-sensitized group, according to the result of skin-prick test and serum specific IgE antibodies to common inhalant allergens monitored every year. The clinical features, drug requirements for systemic steroids, frequency of admission and degree of airway hyper-responsiveness were compared between the two groups. RESULTS: Thirteen (36.1%) of 36 patients with TDI-asthma developed new sensitization to common inhalant allergens during follow-up periods. The mean onset time was 4.93 ± 2.49 years. The prevalence of atopic status and allergic rhinitis tended to be higher in newly-sensitized group. The duration of asthmatic symptoms before the diagnosis was significantly longer in newly-sensitized group (p<0.05). The drug requirements for systemic steroids during the follow-up period to control asthmatic symptoms tended to be increased after the new sensitization in newly-sensitized group. CONCLUSIONS: The development of new sensitization to common inhalant allergen in TDI-asthma may be associated with chronic persistent asthmatic symptoms. New sensitization to common inhalant allergens should be monitored regularly in TDI induced asthmatic patients.","abstract_html":"BACKGROUND: It has been reported that half of toluene diisocyanate (TDI)-induced asthma patients had persistent asthmatic symptoms even after complete avoidance. We hypothesized that new sensitization to common inhalant allergens may contribute to persistent and aggravation of asthmatic symptoms. OBJECTIVE: The aim of this study is to investigate the prevalence and clinical significance of new sensitization to common inhalant allergens in patients with TDI-induced asthma. SUBJECTS AND METHODS: Thirty-six TDI induced asthma patients who had been followed for more than three years were enrolled. They were classified into two groups, newly-sensitized group and not-sensitized group, according to the result of skin-prick test and serum specific IgE antibodies to common inhalant allergens monitored every year. The clinical features, drug requirements for systemic steroids, frequency of admission and degree of airway hyper-responsiveness were compared between the two groups. RESULTS: Thirteen (36.1%) of 36 patients with TDI-asthma developed new sensitization to common inhalant allergens during follow-up periods. The mean onset time was 4.93 ± 2.49 years. The prevalence of atopic status and allergic rhinitis tended to be higher in newly-sensitized group. The duration of asthmatic symptoms before the diagnosis was significantly longer in newly-sensitized group (p&lt;0.05). The drug requirements for systemic steroids during the follow-up period to control asthmatic symptoms tended to be increased after the new sensitization in newly-sensitized group. CONCLUSIONS: The development of new sensitization to common inhalant allergen in TDI-asthma may be associated with chronic persistent asthmatic symptoms. New sensitization to common inhalant allergens should be monitored regularly in TDI induced asthmatic patients.","abstract_has_math":false,"creators":["박, 한정"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["박, 해심","대학원 의학과","104514"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2011,"date_issued":"2011-03-10T01:00:34Z","date_published":"2011-03-10T01:00:34Z","updated_at":"2026-07-24T00:51:24Z","subjects":["Toluene diisocyanate","new sensitization","prognosis","TDI","Isocyanate"],"languages":["ko"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000001917","000000001917"],"render_values":[{"text":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000001917","href":"http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000001917","code":true},{"text":"000000001917","href":null,"code":true}]}]},"links":{"outbound_url":"http://repository.ajou.ac.kr/handle/201003/1627","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["박, 해심","대학원 의학과","104514","박, 한정"]},{"key":"dc:creator","label":"Author","values":["박, 한정"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2011-03-10T01:00:34Z","2007"]},{"key":"dc:type","label":"Dc Type","values":["Thesis","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Toluene diisocyanate","new sensitization","prognosis","TDI","Isocyanate"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["ko"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://repository.ajou.ac.kr/handle/201003/1627","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000001917","000000001917"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["BACKGROUND: It has been reported that half of toluene diisocyanate (TDI)-induced asthma patients had persistent asthmatic symptoms even after complete avoidance. We hypothesized that new sensitization to common inhalant allergens may contribute to persistent and aggravation of asthmatic symptoms. OBJECTIVE: The aim of this study is to investigate the prevalence and clinical significance of new sensitization to common inhalant allergens in patients with TDI-induced asthma. SUBJECTS AND METHODS: Thirty-six TDI induced asthma patients who had been followed for more than three years were enrolled. They were classified into two groups, newly-sensitized group and not-sensitized group, according to the result of skin-prick test and serum specific IgE antibodies to common inhalant allergens monitored every year. The clinical features, drug requirements for systemic steroids, frequency of admission and degree of airway hyper-responsiveness were compared between the two groups. RESULTS: Thirteen (36.1%) of 36 patients with TDI-asthma developed new sensitization to common inhalant allergens during follow-up periods. The mean onset time was 4.93 ± 2.49 years. The prevalence of atopic status and allergic rhinitis tended to be higher in newly-sensitized group. The duration of asthmatic symptoms before the diagnosis was significantly longer in newly-sensitized group (p<0.05). The drug requirements for systemic steroids during the follow-up period to control asthmatic symptoms tended to be increased after the new sensitization in newly-sensitized group. CONCLUSIONS: The development of new sensitization to common inhalant allergen in TDI-asthma may be associated with chronic persistent asthmatic symptoms. New sensitization to common inhalant allergens should be monitored regularly in TDI induced asthmatic patients.","배경 및 목적: Toluene diisocyanate (TDI)-천식 환자의 50% 이상에서 노출회피 및 적절한 약물치료에도 천식 상태가 지속되나 그 기전에 대해 확실히 밝혀진 것은 없다. 저자들은 TDI-천식의 질병경과 중 새롭게 발생하는 흡입성 항원에 대한 감작이 천식 증상의 악화를 유발할 수 있을 것으로 가정하고, 새로운 감작의 감작률 및 예측인자를 조사하고 질병의 예후에 미치는 영향을 관찰하고자 하였다. 대상 및 방법: TDI-천식으로 진단받고, 3년 이상 추적관찰한 36명을 대상으로 하였다. 이들은 모두 원인물질로부터 완전 회피와 적절한 약물치료를 하고 있었으며, 추적관찰 기간중 피부단자시험 및 흡입성 항원에 대한 특이 IgE를 측정하여 흡입성 항원에 새로 감작된 군과 감작이 발생하지 않은 군으로 분류하여, 두 군간의 임상 특징과 치료경과를 비교하였다. 결과: TDI-천식 환자 36명중 13명(36.1%)에서 새로이 흡입성 항원에 대한 감작이 발생하였으며, 두 군간에 성별, 나이, 진단 당시의 폐기능검사, PC20 methacholine치 및 혈청 총 IgE, TDI 노출력, 천식 유병기간의 차이는 없었다. 감작군에서 알레르기비염이 84.6%, 아토피가 61.5%로 비감작군에서의 52.2%, 45.5%보다 높은 경향을 보였고, 전신스테로이드 요구량은 감작군에서 381.1 ± 888.5 mg/month로 비감작군의 148.1 ± 231.7 mg/month에 비하여 더 많은 경향을 보였으며, 감작군에서 감작전 13.95 ± 13.12 mg/year에 비해 감작후 37.10 ± 35.74 mg/year으로 더 증가한 경향을 보였으나 통계적으로 유의한 차이는 없었다(p>0.05, respectively). 결론: TDI-천식의 질병경과 중 1/3의 환자에서 새로이 흡입성 항원에 대한 감작이 관찰되었고, 이는 천식 증상의 악화를 유발하여 천식증상의 지속에 기여할 가능성을 관찰하였으며, 보다 많은 환자를 대상으로 한 추적관찰이 필요하다.","\"Ⅰ.서론 = 1 Ⅱ.연구대상 및 방법 = 3 A.연구대상 = 3 B. 방법 = 3 1.폐기능 검사와 메타콜린 기관지 유발시험 = 3 2.알레르기 피부단자시험 = 4 3.흡입성 항원에 대한 특이 IgE 항체 및 혈청 총 IgE 항체 측정 = 5 4.신감작의 정의 = 5 5.흡입성 항원에 대한 신감작이 천식 경과에 미치는 영향 평가 = 6 C.통계분석 = 6 Ⅲ.결과 = 7 Ⅳ.고찰 = 12 Ⅴ.결론 = 17 참고문헌 = 18 ABSTRACT = 21\"","Master"]},{"key":"dc:title","label":"Title","values":["The Prevalence and Clinical Significance of Newly Sensitization to Inhalant Allergens in Toluene Diisocyanate-induced Asthmatic Patients","Isocyanate에 의한 직업성천식 환자에서 흡입성 항원에 대한"]}]}],"canonical_facts":{"dc:contributor":["박, 해심","대학원 의학과","104514","박, 한정"],"dc:creator":["박, 한정"],"dc:date":["2011-03-10T01:00:34Z","2007"],"dc:description":["BACKGROUND: It has been reported that half of toluene diisocyanate (TDI)-induced asthma patients had persistent asthmatic symptoms even after complete avoidance. We hypothesized that new sensitization to common inhalant allergens may contribute to persistent and aggravation of asthmatic symptoms. OBJECTIVE: The aim of this study is to investigate the prevalence and clinical significance of new sensitization to common inhalant allergens in patients with TDI-induced asthma. SUBJECTS AND METHODS: Thirty-six TDI induced asthma patients who had been followed for more than three years were enrolled. They were classified into two groups, newly-sensitized group and not-sensitized group, according to the result of skin-prick test and serum specific IgE antibodies to common inhalant allergens monitored every year. The clinical features, drug requirements for systemic steroids, frequency of admission and degree of airway hyper-responsiveness were compared between the two groups. RESULTS: Thirteen (36.1%) of 36 patients with TDI-asthma developed new sensitization to common inhalant allergens during follow-up periods. The mean onset time was 4.93 ± 2.49 years. The prevalence of atopic status and allergic rhinitis tended to be higher in newly-sensitized group. The duration of asthmatic symptoms before the diagnosis was significantly longer in newly-sensitized group (p<0.05). The drug requirements for systemic steroids during the follow-up period to control asthmatic symptoms tended to be increased after the new sensitization in newly-sensitized group. CONCLUSIONS: The development of new sensitization to common inhalant allergen in TDI-asthma may be associated with chronic persistent asthmatic symptoms. New sensitization to common inhalant allergens should be monitored regularly in TDI induced asthmatic patients.","배경 및 목적: Toluene diisocyanate (TDI)-천식 환자의 50% 이상에서 노출회피 및 적절한 약물치료에도 천식 상태가 지속되나 그 기전에 대해 확실히 밝혀진 것은 없다. 저자들은 TDI-천식의 질병경과 중 새롭게 발생하는 흡입성 항원에 대한 감작이 천식 증상의 악화를 유발할 수 있을 것으로 가정하고, 새로운 감작의 감작률 및 예측인자를 조사하고 질병의 예후에 미치는 영향을 관찰하고자 하였다. 대상 및 방법: TDI-천식으로 진단받고, 3년 이상 추적관찰한 36명을 대상으로 하였다. 이들은 모두 원인물질로부터 완전 회피와 적절한 약물치료를 하고 있었으며, 추적관찰 기간중 피부단자시험 및 흡입성 항원에 대한 특이 IgE를 측정하여 흡입성 항원에 새로 감작된 군과 감작이 발생하지 않은 군으로 분류하여, 두 군간의 임상 특징과 치료경과를 비교하였다. 결과: TDI-천식 환자 36명중 13명(36.1%)에서 새로이 흡입성 항원에 대한 감작이 발생하였으며, 두 군간에 성별, 나이, 진단 당시의 폐기능검사, PC20 methacholine치 및 혈청 총 IgE, TDI 노출력, 천식 유병기간의 차이는 없었다. 감작군에서 알레르기비염이 84.6%, 아토피가 61.5%로 비감작군에서의 52.2%, 45.5%보다 높은 경향을 보였고, 전신스테로이드 요구량은 감작군에서 381.1 ± 888.5 mg/month로 비감작군의 148.1 ± 231.7 mg/month에 비하여 더 많은 경향을 보였으며, 감작군에서 감작전 13.95 ± 13.12 mg/year에 비해 감작후 37.10 ± 35.74 mg/year으로 더 증가한 경향을 보였으나 통계적으로 유의한 차이는 없었다(p>0.05, respectively). 결론: TDI-천식의 질병경과 중 1/3의 환자에서 새로이 흡입성 항원에 대한 감작이 관찰되었고, 이는 천식 증상의 악화를 유발하여 천식증상의 지속에 기여할 가능성을 관찰하였으며, 보다 많은 환자를 대상으로 한 추적관찰이 필요하다.","\"Ⅰ.서론 = 1 Ⅱ.연구대상 및 방법 = 3 A.연구대상 = 3 B. 방법 = 3 1.폐기능 검사와 메타콜린 기관지 유발시험 = 3 2.알레르기 피부단자시험 = 4 3.흡입성 항원에 대한 특이 IgE 항체 및 혈청 총 IgE 항체 측정 = 5 4.신감작의 정의 = 5 5.흡입성 항원에 대한 신감작이 천식 경과에 미치는 영향 평가 = 6 C.통계분석 = 6 Ⅲ.결과 = 7 Ⅳ.고찰 = 12 Ⅴ.결론 = 17 참고문헌 = 18 ABSTRACT = 21\"","Master"],"dc:identifier":["http://repository.ajou.ac.kr/handle/201003/1627","http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000001917","000000001917"],"dc:language":["ko"],"dc:subject":["Toluene diisocyanate","new sensitization","prognosis","TDI","Isocyanate"],"dc:title":["The Prevalence and Clinical Significance of Newly Sensitization to Inhalant Allergens in Toluene Diisocyanate-induced Asthmatic Patients","Isocyanate에 의한 직업성천식 환자에서 흡입성 항원에 대한"],"dc:type":["Thesis","Theses"]},"updated_at":"2026-07-24T00:51:24Z"}